Objective To analyze the therapeutic efficacy of ginkgolide combined with levodopa and benserazide in the treatment of Parkinson's disease.Methods A total of 100 patients with Parkinson's disease admitted to the Department of Neurology of Affiliated Hospital of Xuzhou Medical University from June 2021 to June 2022 were selected as the study objects,and they were divided into control group and study group of 50 cases each according to different treatment methods.The control group was orally administered levodopa and benserazide tablets,and the study group was coadministered with ginkgolide injection on the basis of the control group.Unified Parkinson's Disease Rating Scale-Ⅲ(UPDRS-Ⅲ)scores,Parkinson's Disease Questionnaire(PDQ-39)scores,serum homocysteine(Hcy)and tumor necrosis factor-α(TNF-α)levels,and the incidence of adverse reactions were compared before and after the treatment in the two groups.Results After treatment,the UPDRS-Ⅲ score of the study group was(27.70±8.58)points,which was lower than that of the control group(32.68±10.30)points,and the PDQ-39 score of the study group was(31.10±4.09)points,which was lower than that of the control group(36.20±6.34)points,and the differences were statistically significant(t=2.627,4.780,P=0.010,0.006).The levels of Hcy and TNF-α decreased in the two groups after treatment and were lower in the study group than in the control group,and the differences were statistically significant(both P＜0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Compared with levodopa and benserazide alone,levodopa and benserazide combined with ginkgolides can improve the quality of life of patients with Parkinson's disease,reduce the risk of cerebrovascu-lar disease and inflammatory response,and the incidence of adverse reactions is small,and the efficacy and safety are guaranteed.
关键词
帕金森病/银杏内酯/多巴丝肼
Key words
Parkinson's disease/Ginkgolides/Levodopa and benserazide
维普
万方数据